Stentor plans compression offering to ease image viewing, transfer needsFirst product set to reach market in MarchA growing number of hospitals and medical centers are seeking to take advantage of the efficiency and workflow benefits of
Stentor plans compression offering to ease image viewing, transfer needsFirst product set to reach market in March
A growing number of hospitals and medical centers are seeking to take advantage of the efficiency and workflow benefits of enterprise-wide digital image distribution. This goal is not easily attained, however. Clinicians often demand to review images at the same resolution as radiologists do, and the bandwidth requirements for large image files pose thorny network problems.
Enter Stentor, a medical informatics company founded last year by two PACS industry veterans with the goal of overcoming these barriers and making low-cost enterprise-wide image distribution a commercial and clinical reality. Stentor has licensed proprietary wavelet compression-based technology developed at the University of Pittsburgh Radiology Informatics Lab (PNN 1/99) and turned it into a Web-based application that can be downloaded and installed on a hospitals intranet. The company expects to have its first commercial product available to customers early next year.
Our goal with this technology is to solve the problem of image distribution across the medical enterprise, said Oran Muduroglu, Stentor president and chief executive officer. Many large PACS sites are still printing film for distribution outside of the radiology department because sending images electronically is still too slow. And as images get larger and more of them need to be sent and retrieved, the servers get overloaded.
Stentor was established in 1998 with $5 million in venture capital from Caduceus Capital Investment of Boston and Sanderling Biomedical Venture Capital of Menlo Park, CA. The University of Pittsburgh also holds an equity stake. The company boasts a strong management team as well.
In addition to Muduroglu, who was vice president of sales and marketing at Cemax-Icon for seven years, John Huffman, former medical marketing manager for Silicon Graphics and co-founder of the wavelet compression firm Aware, serves as chief technical officer. Rounding out the team is Dr. Paul Chang, director of radiology informatics at the University of Pittsburgh Medical Center and a well-known figure in the field of medical informatics. Chang is not a Stentor employee, but serves as the companys executive clinical advisor.
Chang is also one of the developers of the iSyntax technology, originally dubbed dynamic transfer syntax (DTS). When UPMC was considering implementing a large-scale PACS network a few years ago, Chang and his colleagues realized early on that their $25 million budget would not be sufficient to meet the image viewing requirements of the medical centers referring physicians, many of whom wanted the same image quality and resolution available in the hospitals radiology department. Rather than deploying a huge network pipeline to handle the large data files and installing multiple $100,000 workstations throughout the hospital, Chang and his colleagues used Java and CORBA technology, along with DICOM libraries from Merge Technologies, to develop a new image-distribution model that allows near real-time delivery of electronic images via standard Ethernet lines to PCs anywhere in the hospital.
When an image request is made, iSyntax automatically retrieves and sends lower resolution versions of the images but allows users to identify specific regions they want to see in higher resolution. This obviates the need for high-bandwidth networks and high-powered workstations and reduces end-user costs without sacrificing image quality or acquisition times, according to the company.
Using iSyntax, you can look at a 2K x 2.5K image within one second, and you can pan and zoom around the image in real-time, all without overwhelming the network, Muduroglu said.
iSyntax was unveiled as a work-in-progress (still called DTS) during the 1998 RSNA meeting, where it received a summa cum laude award. Since being licensed to Stentor, the technology has undergone some reengineering to make it a more commercially viable product. The only installation at this time is at UPMC, which has served as the primary beta site. Stentor filed a 510(k) application with the Food and Drug Administration in August and expects to receive marketing clearance for iSyntax by November, prior to the RSNA meeting. A full commercial release is scheduled for March 1, 2000, following several more months of beta testing at up to 30 sites, including UPMC, Stanford University, and the University of California, Davis. The company has also filed six patents, which are pending.
Once FDA clearance is gained, Stentor plans to use a unique business model to distribute its products. The company will make the iSyntax technology available directly to customers through iSite, a client application service that self-installs, self-diagnoses, and is maintained via a real-time connection to Stentors Quality Engineering Center. iSite can be downloaded via the Internet, installed on a hospitals internal intranet server, and used for one month on a trial basis, free of charge. Customers who decide to continue using it will then be billed on a per-use/per-image basis. As part of this service, Stentor is making a cost-distribution model available on its Web site so that CIOs and other prospective customers can determine their potential savings prior to installing the iSite system.
Our goal is to offer close to an order of magnitude cost savings using this technology versus how they do it now, Muduroglu said.
OEM relationships will also play a key role in Stentors production distribution plans. The company is talking to healthcare information systems vendors (primarily those already working with electronic patient records) and PACS companies that will attach the iSyntax technology to the back end of their systems to enhance image distribution. Stentor expects to announce these partnerships at the RSNA meeting in late November. The company also plans to demonstrate a full-field mammography viewing workstation enabled with iSyntax at the RSNA show.
385 Oyster Point Blvd., Suite 8B
South San Francisco, CA 94080
650/866-2125
fax: 650/866-4197
stentorsoft.com
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.